Selected trends in head and neck cancer epidemiology in Slovakia – an international comparison

Czech version

Authors: M. Ondrušová ^1,2; M. Suchanský ²; D. Ondruš ³; S. Marková ^1,4
Authors‘ workplace: Katedra preventívnej a klinickej medicíny, Fakulta verejného zdravotníctva, Slovenská zdravotnícka univerzita, Bratislava, Slovenská republika ¹; Oddelenie epidemiológie a štatistiky, Pharm-In, spol. s r. o., Bratislava, Slovenská republika ²; I. onkologická klinika LF UK a OÚSA, Bratislava, Slovenská republika ³; Universitätszahnklinik, Medizinische Universität Wien, Wien, Austria ⁴
Published in: Klin Onkol 2023; 36(2): 135-142
Category: Original Articles
doi: https://doi.org/10.48095/ccko2023135

Overview

Background: Head-and-neck malignant neoplasms (diagnosis group C00-C14, according to ICD-10) form a heterogeneous group of diseases with close anatomical localization. The incidence is twice to three times higher in men than in women and is increasing worldwide. Objective: The aim of our analysis was to estimate changes of incidence and mortality rates of head-and-neck malignancies associated with anatomical topographic regions over the time as well as to compare these indicators in different selected countries of the world. Secondary endpoints included the assessment of patients’ age distribution, clinical stages of newly diagnosed cases, and point prevalence of the disease in the Slovak Republic (SR). Material and methods: The data base for the calculations was obtained from national databases and outputs of the National Cancer Registry (NCR) of the SR (with summary data available from the National Epidemiological Portal of Malignant Tumors, which analyzed data from 1984–2003 and was available until 2009, the remaining data were obtained from annual analyses of the NCR of the SR and the National Centre for Health Information (NCZI)), from the Statistical Office of the SR, and from the IARC WHO global database outputs on incidence, mortality, prevalence and survival of the patients. Incidence and mortality data in the SR were available up to 2012 (including) and up to 2021 (including), respectively. A log-linear joinpoint regression model was used to analyze the development of incidence and mortality rates over time by using Joinpoint Regression Program software. To achieve maximum precision in the estimated total surviving population of patients with head and neck malignant neoplasms, a model was developed to calculate the point (overall) prevalence based on absolute numbers of long-term registered national counts of newly diagnosed patients, mortality from the disease, overall mortality, and survival probability. The representation of clinical stages of head and neck carcinoma in the SR was compiled from available national data (2000–2012) and from predictions and does not consider changes in TNM classifications over the time. Results: The age-adjusted (to the world standard population, ASR-W) incidence rate and the age-adjusted (ASR-W) mortality rate of head-and-neck malignant tumors in the SR have shown a significantly decreasing tendency in men since 1990; however, in women both of these indicators have shown a significant increasing tendency, especially the significantly growing incidence since 2004. In 2012, the overall age-adjusted incidence and mortality rate of head-and-neck cancers in the SR were significantly higher in males (ASR-W incidence 22.6/100,000 and ASR-W mortality 15.26/100,000) compared to females (ASR-W incidence 4.21/100,000 and ASR-W mortality 1.52/100,000). More than 75% of newly diagnosed cases are already in advanced and metastatic clinical stages, which is the most unfavourable survival factor. The absolute prevalence of these patients in the SR was estimated to be N = 9,395 in the year 2021. Conclusion: It is necessary to get a current and well evaluated epidemiological overviews to be able to plan preventive and intervention programs in oncology.

Keywords:

incidence – mortality – prevalence – head and neck malignancies

Sources

1. Partlová S, Bouček J, Kloudová K et al. Immune system in patients with head and neck carcinoma. Klin Onkol 2015; 28 (Suppl 4): 4S86–4S94. doi: 10.14735/amko20154s86.

2. Sehnal B, Podlešák T, Kmoníčková E et al. Anogenital HPV infection as the potential risk factor for oropharyngeal carcinoma. Klin Onkol 2018; 32 (2): 103–109. doi: 10.14735/amko2018103.

3. Menezes FDS, Fernandes GA, Antunes JLF et al. Global incidence trends in head and neck cancer for HPV-related and unrelated subsites: a systematic review of population-based studies. Oral Oncol 2021; 115: 105177. doi: 10.1016/j.oraloncology.2020.105177.

4. Stenson KM, Brockstein BE, Shah S. Epidemiology and risk factors for head and neck cancer. [online]. Available from: https: //www.uptodate.com/contents/epidemiology-and-risk-factors-for-head-and-neck-cancer.

5. Harris R. Epidemiology of cancers of the lip, oral cavity & pharynx. In: Harris R (ed). Global epidemiology of cancer. Burlington, MA (USA): Jones & Bartlett Publishers 2016.

6. Chang ET, Adami H-O. Nasopharyngeal cancer. In: Adami H-O, Hunter DJ, Lagiou P, Mucci L (eds). Textbook of cancer epidemiology. New York: Oxford University Press 2018: 489–504.

7. Deschler DG, Moore MG, Smith RV (eds). Quick reference guide to TNM staging of head and neck cancer and neck dissection classification. Alexandria, VA (USA): American Academy of Otolaryngology – Head and Neck Surgery American Head and Neck Society 2014.

8. Du E, Mazul AL, Farquhar D et al. Long-term survival in head and neck cancer: impact of site, stage, smoking, and human papillomavirus status. Laryngoscope 2019; 129 (11): 2506–2513. doi: 10.1002/lary.27807.

9. Gatta G, Botta L, Sánchez MJ et al. Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: the EUROCARE-5 population-based study. Eur J Cancer 2015; 51 (15): 2130–2143. doi: 10.1016/j.ejca.2015.07.043.

10. Národný onkologický register Slovenskej republiky – Prezentácia výstupov. [online]. Dostupné z: https: //iszi.nczisk.sk/nor.sr/.

11. Štatistický úrad Slovenskej republiky. Pramenné dielo – príčiny smrti. [online]. Dostupné z: https: //slovak.statistics.sk.

12. Kim H-J, Fay MP, Feuer EJ et al. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000; 19 (3): 335–351. doi: 10.1002/ (sici) 1097-0258 (20000215) 19: 3<335:: aid-sim336>3.0.co; 2-z.

13. National Cancer Institute. Joinpoint Regression Program, Version 4.9.0.0. [online]. Available from: https: //surveillance.cancer.gov/joinpoint/.

14. Clegg LX, Hankey BF, Tiwari R et al. Estimating average annual percent change in trend analysis. Stat Med 2009; 28 (29): 3670–3678. doi: 10.1002/sim.3733.

15. Ferlay J, Ervik M, Lam F et al. Global Cancer Observatory: cancer today. [online]. Available from: https: //gco.iarc.fr/today.

16. Dušek L, Mužík J, Kubásek M et al. Epidemiologie zhoubných nádorů v České republice. [online]. Dostupné z: http: //www.svod.cz.

17. Ondrušová M, Suchanský M, Kuraj J. Vybrané epidemiologické aspekty zhubných nádorov pery, ústnej dutiny a hltana. [online]. Dostupné z: www.pharmin.sk.

18. Cancer Today. Data & methods. [online]. Available from: https: //gco.iarc.fr/today/data-sources-methods.

19. State of Health in the EU. Slovakia: country health profile 2021. [online]. Available from: https: //eurohealthobservatory.who.int/publications/m/slovakia-country-health-profile-2021.

20. Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71 (3): 209–249. doi: 10.3322/caac.21 660.

21. Barnes B, Buttmann-Schweiger N, Fiebig J et al. Bericht zum Krebsgeschehen in Deutschland 2016. [online]. Available from: https: //edoc.rki.de/bitstream/handle/176904/3264/28oaKVmif0wDk.pdf?sequence= 1&isAllowed=y.

22. Jansen L, Moratin J, Waldmann A et al. Oral and pharyngeal cancer: incidence, mortality, and survival in Germany. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2021; 64 (8): 941–950. doi: 10.1007/s00103-021-03368-z.

23. Gillison ML, Alemany L, Sniders PJF et al. Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. Vaccine 2012; 30 (Suppl 5): F34–54. doi: 10.1016/j.vaccine.2012.05. 070.

24. Kurinec F, Weismanová E. Súčasný pohľad na epidemiológiu nádorov hlavy a krku. Via Pract 2015; 12 (5): 209–211.

25. Tumban E. A current update on human papillomavirus-associated head and neck cancers. Viruses 2019; 11 (10): 922. doi: 10.3390/v11100922.

26. D’Souza G, Wentz A, Kluz N et al. Sex differences in risk factors and natural history of oral human papillomavirus infection. J Infect Dis 2016; 213 (12): 1893–1896. doi: 10.1093/infdis/jiw063.

27. Deschler DG, Richmon JD, Khariwala SS et al. The “new” head and neck cancer patient – young, nonsmoker, nondrinker, and HPV positive: evaluation. Otolaryngol Head Neck Surg 2014; 151 (3): 375–380. doi: 10.1177/0194599814538605.

28. Hussein AA, Helder MN, De Visscher JG et al. Global incidence of oral and oropharynx cancer in patients younger than 45 years versus older patients: a systematic review. Eur J Cancer 2017; 82: 115–127. doi: 10.1016/j.ejca.2017.05.026.